Progressive multifocal leukoencephalopathy in a heart transplant recipient following rituximab therapy for antibody-mediated rejection

American Journal of Transplantation

Volumn 13, Issue 4, 2013, Pages 1075-1079

  Loyaga Rendon, R Y ^a   Taylor, D O ^b   Koval, C E ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antibody mediated rejection; heart transplantation; leukoencephalopathy; rituximab

Indexed keywords

COMPLEMENT COMPONENT C4D; CYCLOSPORIN; EFALIZUMAB; GLUCOSE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MIRTAZAPINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PREDNISONE; PROTEIN; RITUXIMAB; STEROID; TACROLIMUS;

ACUTE ANTIBODY MEDIATED REJECTION; ACUTE GRAFT REJECTION; ACUTE HEART FAILURE; ADULT; ARTICLE; BALANCE DISORDER; CARDIAC GRAFT REJECTION; CASE REPORT; CAUCASIAN; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONFUSION; CONGESTIVE CARDIOMYOPATHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DYSPNEA; ECHOCARDIOGRAPHY; ERYTHROCYTE; HEART CATHETERIZATION; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; JC VIRUS; LEUKOCYTE; MALE; MOTOR DYSFUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SIDE EFFECT; STEROID THERAPY; TREMOR; VASCULAR DISEASE; WEIGHT GAIN; WHITE MATTER LESION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COGNITION DISORDERS; FATAL OUTCOME; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIANSERIN; MIDDLE AGED; PLASMAPHERESIS;

EID: 84875702563     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12153     Document Type: Article

References (49)

1. Krupp LB, Lipton RB, Swerdlow ML, Leeds NE, Llena J,. Progressive multifocal leukoencephalopathy: Clinical and radiographic features. Ann Neurol 1985; 17: 344-349. (Pubitemid 15079060)
2. Sahraian MA, Radue EW, Eshaghi A, Besliu S, Minagar A,. Progressive multifocal leukoencephalopathy: A review of the neuroimaging features and differential diagnosis. Euro J Neurol 2012; 19: 1060-1069.
3. Singh N, Bonham A, Fukui M,. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. Transplantation 2000; 69: 467-472. (Pubitemid 30129574)
4. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH,. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1: 1257-1260. Epub 1971/06/19. eng.
5. Dorries K,. Progressive multifocal leucoencephalopathy: Analysis of JC virus DNA from brain and kidney tissue. Virus Res 1984; 1: 25-38. Epub 1984/01/01. eng. (Pubitemid 14077364)
6. Yogo Y, Kitamura T, Sugimoto C, et al. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol 1990; 64: 3139-3143. Epub 1990/06/01. eng. (Pubitemid 20171319)
7. Jing D, Oelschlaegel U, Ordemann R, et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 2010; 45: 1489-1496. Epub 2010/01/26. eng.
8. Cettomai D, McArthur JC,. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009; 66: 255-258. Epub 2009/02/11. eng.
9. Sabath BF, Major EO,. Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186 (Suppl 2): S180-S186. Epub 2002/11/09. eng. (Pubitemid 35370479)
10. Kedar S, Berger JR,. The changing landscape of progressive multifocal leukoencephalopathy. Curr Infect Dis Rep 2011; 13: 380-386. Epub 2011/05/24. eng.
11. Taguchi F, Kajioka J, Miyamura T,. Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol 1982; 26: 1057-1064. Epub 1982/01/01. eng. (Pubitemid 13149088)
12. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71: 115-123. Epub 2003/07/15. eng. (Pubitemid 37121921)
13. Astrom KE, Mancall EL, Richardson EP, Jr,. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81: 93-111. Epub 1958/03/01. eng.
14. Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J,. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010; 75: 1326-1332. Epub 2010/10/13. eng.
15. Berger JR, Kaszovitz B, Post MJ, Dickinson G,. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987; 107: 78-87. (Pubitemid 17098643)
16. Lang W, Miklossy J, Deruaz JP, et al. Neuropathology of the acquired immune deficiency syndrome (AIDS): A report of 135 consecutive autopsy cases from Switzerland. Acta Neuropathol 1989; 77: 379-390. (Pubitemid 19070180)
17. Berger JR, Pall L, Lanska D, Whiteman M,. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4: 59-68. Epub 1998/04/08. eng. (Pubitemid 28081579)
18. Khanna N, Elzi L, Mueller NJ, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009; 48: 1459-1466. Epub 2009/04/08. eng.
19. Clifford DB, Yiannoutsos C, Glicksman M, et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999; 52: 623-625. Epub 1999/02/20. eng. (Pubitemid 29075615)
20. Major EO,. History and current concepts in the pathogenesis of PML. Cleveland Clin J Med 2011; 78 (Suppl 2): S3-S7. Epub 2011/12/14. eng.
21. Rudick RA,. Multiple sclerosis, natalizumab, and PML: Helping patients decide. Cleveland Clin J Med 2011; 78 (Suppl 2): S18-S23. Epub 2011/12/14. eng.
22. Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18: 143-152. Epub 2012/02/09. eng.
23. Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG,. Quantitative risk-benefit analysis of natalizumab. Neurology 2008; 71: 357-364. Epub 2008/07/30. eng.
24. Schon MP,. Efalizumab in the treatment of psoriasis: Mode of action, clinical indications, efficacy, and safety. Clin Dermatol 2008; 26: 509-514. Epub 2008/08/30. eng.
25. Molloy ES,. PML and rheumatology: The contribution of disease and drugs. Cleveland Clin J Med 2011; 78 (Suppl 2): S28-S32. Epub 2011/12/14. eng.
26. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195. Epub 1997/10/06. eng. (Pubitemid 27392702)
27. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK,. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005; 62: 258-264. Epub 2005/02/16. eng. (Pubitemid 40204747)
28. Reinsmoen NL, Lai CH, Vo A, Jordan SC,. Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discov Med 2012; 13: 267-273. Epub 2012/05/01. eng.
29. Montgomery RA, Cozzi E, West LJ, Warren DS,. Humoral immunity and antibody-mediated rejection in solid organ transplantation. Semin Immunol 2011; 23: 224-234. Epub 2011/10/01. eng.
30. Blume OR, Yost SE, Kaplan B,. Antibody-mediated rejection: Pathogenesis, prevention, treatment, and outcomes. J Transplant 2012; 2012: 201754. Epub 2012/05/01. eng.
31. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840. Epub 2009/03/07. eng.
32. Flomenbaum MA, Jarcho JA, Schoen FJ,. Progressive multifocal leukoencephalopathy fifty-seven months after heart transplantation. J Heart Lung Transplant 1991; 10: 888-893. Epub 1991/11/01. eng.
33. Verhelst X, Vanhooren G, Vanopdenbosch L, et al. Progressive multifocal leukoencephalopathy in liver transplant recipients: A case report and review of the literature. Transpl Int 2011; 24: e30-e34. Epub 2010/12/08. eng.
34. Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008; 86: 1474-1478. Epub 2008/11/27. eng.
35. Pelosini M, Focosi D, Rita F, et al. Progressive multifocal leukoencephalopathy: Report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol 2008; 87: 405-412. Epub 2007/12/08. eng.
36. Pavlovic AM, Bonaci-Nikolic B, Kozic D, et al. Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency. Lupus 2012; 21: 100-102. Epub 2011/10/07. eng.
37. Aksamit AJ, Jr., de Groen PC,. Cyclosporine-related leukoencephalopathy and PML in a liver transplant recipient. Transplantation 1995; 60: 874-876. Epub 1995/10/27. eng.
38. Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011; 70: 305-322. Epub 2011/08/09. eng.
39. Baek CH, Yang WS, Park KS, Han DJ, Park JB, Park SK,. Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation. Nephron Extra 2012; 2: 66-75. Epub 2012/05/24. eng.
40. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72: 402-409. Epub 2009/02/04. eng.
41. Calabrese L,. A rational approach to PML for the clinician. Cleveland Clin J Med 2011; 78 (Suppl 2): S38-S41. Epub 2011/12/14. eng.
42. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998; 338: 1345-1351. Epub 1998/05/08. eng. (Pubitemid 28216663)
43. Garrote FJ, Molina JA, Lacambra C, Mollejo M, Madero S, del Ser T,. [The inefficacy of zidovudine (AZT) in progressive multifocal leukoencephalopathy (PML) associated with the acquired immunodeficiency syndrome (AIDS)]. Revista Clinica Espanola 1990; 187: 404-407. Epub 1990/11/01. Ineficacia de la zidovudina (AZT) en la leucoencefalopatia multifocal progresiva (LMP) asociada al sindrome de inmunodeficiencia adquirida (SIDA). spa.
44. Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. Aids 2002; 16: 1791-1797. Epub 2002/09/10. eng.
45. Stuve O, Marra CM, Cravens PD, et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: Possible interventions. Arch Neurol 2007; 64: 169-176. Epub 2007/02/14. eng.
46. Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrobial Agents Chemother 2009; 53: 1840-1849. Epub 2009/03/05. eng.
47. Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306: 1380-1383. Epub 2004/11/20. eng. (Pubitemid 39532516)
48. Verma S, Cikurel K, Koralnik IJ, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 2007; 196: 709-711. Epub 2007/08/04. eng. (Pubitemid 47293853)
49. Balduzzi A, Lucchini G, Hirsch HH, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 2011; 46: 987-992.